publication date: Dec. 22, 2010

In this issue: 

As ImClone Investigation Continues, FDA Combines Drugs, Biologics Review; Memo Describes “Lengthy Process” That Led To FDA Decision; Oncology Community Praises FDA Move;

ASCO, NCCS Call For Oncology Center;

Zerhouni Appoints Two Institute Directors;

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard;

NCI Program Develops Bioinformatics Tool To Design Cancer Drugs;

Funding Opportunities

(8-page issue).

Download (PDF 206KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.